AstraZeneca's investigational oral GLP-1 receptor agonist, elecoglipron, demonstrated significant weight loss and improved diabetes control in two Phase 2b trials. The VISTA study showed an average weight reduction of up to 11.8% in obese or overweight adults, while the SOLSTICE trial reported a 1.9% drop in HbA1c and 7.7% weight loss in Type 2 diabetes patients. Side effects were mostly mild gastrointestinal issues. AstraZeneca plans to advance elecoglipron into Phase 3 trials, including studies on cardiovascular and kidney outcomes.
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
AstraZeneca CEO Pascal Soriot highlighted that artificial intelligence (AI) is significantly enhancing the company's ability to develop medicines faster and make smarter research decisions. AI tools help identify promising drug targets, optimize mole...
Sunshine Silver Mining & Refining saw its shares rise 27% during its debut on the New York Stock Exchange, signaling strong investor interest. AstraZeneca celebrated its transfer to the NYSE, noted as the largest by market capitalization in the excha...
